Author: OurCrowd

[Appdome in PR Newswire] Appdome unleashes most comprehensive Mobile bot defense profile for industry standard web application firewalls

Apr 29, 2025 |

SAN FRANCISCO, April 29, 2025 /PRNewswire/ — Appdome, the leader in protecting mobile businesses, today announced at RSAC 2025 that its AI-Native MobileBOT™ Defense solution now offers the most comprehensive mobile bot defense profile on the market. Capable of evaluating 400+ attack vectors in Android & iOS apps, OSs, devices, user interfaces and networks, Appdome’s new MobileBOT™ defense profile allows network security teams to not only stop brute force bot and credential stuffing attacks but also stop hyper targeted, spear phishing, account takeover (ATO), KYC fraud, on-device fraud (ODF), and deepfake threats in real time across account creation, login, password reset, payment and other critical API endpoints. Read...

Read More

[RO in PR Newswire] Charles Barkley partners with RO as glp-1 celebrity ambassador

Apr 29, 2025 |

NEW YORK, April 29, 2025 /PRNewswire/ — Ro, the leading direct-to-patient telehealth company, today announced that NBA Hall of Famer and five-time Sports Emmy Award winning broadcaster Charles Barkley is joining on as a GLP-1 celebrity ambassador. The partnership is deeply personal for Barkley, who is restarting his weight loss journey with Ro after facing significant barriers to treatment access and weight regain. Read...

Read More

[RO in PR Newswire] RO integrates with Novocare® pharmacy to provide seamless access to Wegovy® at the lowest cash price

Apr 29, 2025 |

NEW YORK, April 29, 2025 /PRNewswire/ — Ro today announced an integration with NovoCare® Pharmacy to provide seamless access to all doses of Wegovy® at the best available cash price of $499 per month. By working directly with Novo Nordisk’s direct-to-patient option NovoCare® Pharmacy, Ro ensures patients have a reliable supply of FDA-approved GLP-1 medication directly from the manufacturer. With Ro’s streamlined experience, patients can consult with a provider and get access to effective GLP-1 medication at the lowest cash price, without ever having to leave the Ro app. Read...

Read More

[Lifeward in GlobeNewswire] First major U.S. commercial health insurer approves purchase of ReWalk 7 Personal Exoskeleton

Apr 29, 2025 |

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 29, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that a major U.S. health insurance company has approved the payment for a ReWalk 7 Personal Exoskeleton for one of its beneficiaries. This decision by one of the largest commercial health insurers in the U.S. marks the first approval for payment of the all-new ReWalk 7 Personal Exoskeleton for individuals with spinal cord injury (“SCI”), which was launched for U.S. sales on April 15, 2025. Read more...

Read More